title: Efficacy of valganciclovir plus cytomegalovirus immune globulin for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
authors.forename: Angela Q
authors.initials: AQ
authors.lastname: Maldonado
authors.forename: Amanda N
authors.initials: AN
authors.lastname: Bitterman
authors.forename: Okechukwu N
authors.initials: ON
authors.lastname: Ojogho
authors.forename: Kurt A
authors.initials: KA
authors.lastname: Bowen
authors.forename: Douglas L
authors.initials: DL
authors.lastname: Weeks
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D016030:Kidney Transplantation; D012189:Retrospective Studies; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; C045781:cytomegalovirus-specific hyperimmune globulin; D000077562:Valganciclovir; D015774:Ganciclovir